Table IV.
Incidence rates of outcomes by follow-up period, treatment group, and age at randomization
| Condition | Group | Incidence per 1000 child days |
|
|---|---|---|---|
| <3.0 years at randomization | ≥3.0 years at randomization | ||
| Influenza season | |||
| Febrile RTI | TIV+PCV7 | 5.2 (3.9 to 6.9) | 5.4 (4.0 to 7.4) |
| TIV+plac | 6.7 (5.4 to 8.4) | 4.9 (3.6 to 6.6) | |
| HBV+plac | 7.2 (5.9 to 8.9) | 6.5 (5.0 to 8.4) | |
| GP visit | TIV+PCV7 | 2.2 (1.4 to 3.3) | 2.2 (1.4 to 3.5) |
| TIV+plac | 2.5 (1.8 to 3.6) | 1.0 (0.5 to 2.1) | |
| HBV+plac | 3.2 (2.3 to 4.3) | 2.5 (1.6 to 3.9) | |
| Antibiotic prescription | TIV+PCV7 | 0.9 (0.5 to 1.6) | 1.3 (0.7 to 2.6) |
| TIV+plac | 1.6 (1.9 to 2.7) | 0.6 (0.2 to 1.7) | |
| HBV+plac | 1.5 (1.0 to 2.4) | 1.1 (0.6 to 2.4) | |
| AOM | TIV+PCV7 | 0.6 (0.2 to 1.3) | 0.5 (0.2 to 1.4) |
| TIV+plac | 0.6 (0.3 to 1.3) | 0.0 | |
| HBV+plac | 1.5 (0.9 to 2.5) | 0.8 (0.4 to 1.7) | |
| Outside influenza season | |||
| Febrile RTI | TIV+PCV7 | 4.4 (3.6 to 5.4) | 3.3 (2.4 to 4.4) |
| TIV+plac | 4.1 (3.3 to 5.0) | 2.7 (1.9 to 3.6) | |
| HBV+plac | 3.4 (2.8 to 4.2) | 3.2 (2.4 to 4.2) | |
| GP visit | TIV+PCV7 | 1.3 (0.9 to 1.8) | 1.1 (0.7 to 1.8) |
| TIV+plac | 1.4 (1.0 to 2.0) | 0.9 (0.5 to 1.6) | |
| HBV+plac | 1.5 (1.0 to 2.0) | 1.5 (0.1 to 2.2) | |
| Antibiotic prescription | TIV+PCV7 | 0.8 (0.5 to 1.2) | 0.7 (0.4 to 1.2) |
| TIV+plac | 0.6 (0.4 to 1.1) | 0.5 (0.2 to 1.0) | |
| HBV+plac | 0.9 (0.6 to 1.3) | 0.8 (0.5 to 1.4) | |
| AOM | TIV+PCV7 | 0.5 (0.3 to 0.8) | 0.4 (0.2 to 0.8) |
| TIV+plac | 0.4 (0.2 to 0.7) | 0.3 (0.2 to 0.9) | |
| HBV+plac | 0.2 (0.1 to 0.5) | 0.3 (0.1 to 0.6) | |